Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$21.64
+0.9%
$23.73
$14.97
$26.58
$2.62B0.661.12 million shs687,432 shs
Morphic Holding, Inc. stock logo
MORF
Morphic
$56.99
$56.76
$19.34
$57.00
$2.85B1.491.27 million shs400 shs
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
$1.10
$1.08
$0.59
$8.08
$36.47M0.1701,788 shsN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$6.47
$6.47
$5.73
$8.75
$644.67M0.01N/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$28.16
+1.6%
$27.42
$18.92
$81.73
$3.17B0.624.03 million shs2.38 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
0.00%-0.64%-14.43%-6.20%+41.35%
Morphic Holding, Inc. stock logo
MORF
Morphic
0.00%0.00%0.00%0.00%+79.04%
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.00%0.00%0.00%0.00%0.00%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.00%+6.18%+4.30%+24.49%-44.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
4.9184 of 5 stars
3.61.00.03.93.23.33.8
Morphic Holding, Inc. stock logo
MORF
Morphic
1.0407 of 5 stars
1.00.00.04.80.03.30.0
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.3593 of 5 stars
4.51.00.04.71.92.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
3.25
Buy$32.8351.73% Upside
Morphic Holding, Inc. stock logo
MORF
Morphic
2.00
Hold$57.000.02% Upside
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
0.00
N/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.00
N/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$87.15209.50% Upside

Current Analyst Ratings Breakdown

Latest CPRX, VKTX, SVA, STSA, and MORF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00
6/5/2025
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/29/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$104.00
4/28/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$95.00 ➝ $75.00
4/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.00
4/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
4/17/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
4/8/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$30.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$491.73M5.37$2.47 per share8.77$6.10 per share3.55
Morphic Holding, Inc. stock logo
MORF
Morphic
$520K5,490.11N/AN/A$12.31 per share4.63
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/A$1.41 per shareN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$448.27M1.44$0.17 per share38.95$120.83 per share0.05
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$7.90 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$163.89M$1.5713.7810.160.8736.91%42.45%36.59%8/6/2025 (Estimated)
Morphic Holding, Inc. stock logo
MORF
Morphic
-$152.10M-$3.50N/AN/AN/AN/A-26.62%-25.74%N/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
-$70.06M-$2.01N/AN/AN/AN/A-115.24%-102.26%N/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
-$99.92MN/A0.00N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.15N/AN/AN/AN/A-14.41%-14.02%7/23/2025 (Estimated)

Latest CPRX, VKTX, SVA, STSA, and MORF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/23/2025Q2 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.44N/AN/AN/AN/AN/A
4/23/2025Q1 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.31-$0.41-$0.10-$0.41N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/AN/AN/AN/AN/A
Morphic Holding, Inc. stock logo
MORF
Morphic
N/AN/AN/AN/AN/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest CPRX, VKTX, SVA, STSA, and MORF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
--$55.007/8/20255/23/20257/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/A
6.14
5.96
Morphic Holding, Inc. stock logo
MORF
Morphic
N/A
24.13
24.13
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/A
7.44
7.44
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
44.25
44.25

Institutional Ownership

CompanyInstitutional Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
79.22%
Morphic Holding, Inc. stock logo
MORF
Morphic
94.25%
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
93.26%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
80121.97 million109.29 millionOptionable
Morphic Holding, Inc. stock logo
MORF
Morphic
10050.09 million37.27 millionOptionable
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
2133.15 million22.81 millionNot Optionable
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
3,26199.64 million86.89 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.31 million107.71 millionOptionable

Recent News About These Companies

VKTX - Viking Therapeutics Inc Sustainability - Morningstar
Futuristic laboratory, doctor or scientist holding glass tube, molecular and DNA structure, genetic research human biology and pharmaceutical technology, medical,science,development biological system — Photo
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
...
VKTX Viking Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Catalyst Pharmaceuticals stock logo

Catalyst Pharmaceuticals NASDAQ:CPRX

$21.64 +0.19 (+0.89%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$21.35 -0.29 (-1.34%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Morphic stock logo

Morphic NASDAQ:MORF

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Satsuma Pharmaceuticals stock logo

Satsuma Pharmaceuticals NASDAQ:STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Sinovac Biotech stock logo

Sinovac Biotech NASDAQ:SVA

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$28.16 +0.44 (+1.59%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$28.04 -0.12 (-0.43%)
As of 07/3/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.